CRTC2 and cancer: Mechanistic studies of the anti-cancer drug, rapamycin, helped identify the TOR genes and found that rapamycin binds to and renders TORC1, and not TORC2 inactive, initiating a myriad of studies that have used rapamycin to examine TORC1 function and distinguish it from TORC2 (Heitman et al. 1991; Stan et al. 1994).